Prognose
Vi har ingen analytikerdata for denne virksomhed.
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
DocMorris raises forecast after 260% rally and improves operating result
The DocMorris share rose by around 260% over twelve months, driven by a markedly improved operating performance. At its capital markets day the company raised its revenue target to about 15% growth, supported by a strong Rx business (over 90% growth in prescription drugs in October) and improved margins. Adjusted EBITDA is expected to be at worst -10m CHF; a small positive was already achieved in the third quarter, and a free-cash-flow break-even is expected for 2027. Investors should note the strong rally and the earlier 200m CHF capital increase. » Mere på deraktionaer.de
DocMorris raises outlook after strong sales and prescription growth
DocMorris increased sales in the third quarter by 21% to CHF 343m and reached CHF 971m in the first nine months (+14%). The prescription drug business grew in Q3 by 78% to CHF 108m, active customers rose by 1.5m to 13.1m. For 2026 the company now expects sales growth of 12–15% (in local currency) and lowers the expected EBITDA loss to below CHF 10m. The share price jumped about 8% and hit a 52-week high. » Mere på deraktionaer.de
Apothekerkammer seizes €110,000 from DocMorris following court rulings
The Apothekerkammer Nordrhein carried out enforcement measures in the Netherlands against DocMorris for over €110,000 after the company was said to have breached final German judgments on advertising and discounts. German pharmacists had previously applied for administrative fines and achieved their enforcement in the Netherlands. DocMorris called the measure an enforcement of administrative fines, intends to appeal, and sees no impact on its operations or financial stability. » Mere på heise.de
Pharmacy chamber seizes €110,000 from DocMorris after breach of German judgments
The Apothekerkammer Nordrhein carried out enforcement measures in the Netherlands for €110,000 after DocMorris was said to have violated final German judgments on advertising and discounts. DocMorris described the action as enforcement of administrative fines, announced it would appeal, and stressed that it has no impact on operations or financial stability. The case is part of the years-long dispute between the online provider based in the Netherlands and German brick-and-mortar pharmacies over competitive conditions and cross-border trade. » Mere på finanzen.net
DocMorris in the Netherlands seized over unpaid fines
A court in Limburg ruled the seizure of accounts belonging to mail-order pharmacy DocMorris lawful after the Apothekerkammer Nordrhein applied for enforcement over unpaid, final administrative fines from Germany. The fines stem from prohibited price advertising, for which Stuttgart imposed several penalties (including €50,000, €60,000 and €100,000); the chamber says unpaid sums run into the millions. DocMorris can appeal within four weeks; the company did not comment on the proceedings. DocMorris is based in Heerlen and generated about €327.2m in revenue on the German market in Q1 2026 (+11.1%). » Mere på t-online.de
Historisk udbytte Udbytte
Alle nøgletal for udbytte Alle nøgletalI 2016 har DocMorris allerede udloddet 0,46 € i udbytte. Den seneste udlodning fandt sted i juni 2016.
Virksomhedstal
I det seneste kvartal havde DocMorris en omsætning på 649,14 mio. € og et nettoresultat på -57,53 mio. €
| (EUR) | juni 2026 | YoY |
|---|---|---|
| Omsætning | 649,14 mio. | - |
| Bruttofortjeneste | 59,51 mio. | - |
| Nettoresultat | -57,53 mio. | - |
| EBITDA | -21,69 mio. | - |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 1,01 mia. € |
Antal aktier | 50,49 mio. |
Højeste/laveste i 52 uger | 21,19 € - 4,25 € |
| Udbytte | Nej |
Beta | 1,86 |
P/E (PE Ratio) | -11,72 |
PEG (PEG Ratio) | -0,12 |
K/I (PB Ratio) | 2,53 |
P/S (PS Ratio) | 0,79 |
Virksomhedsprofil
Zur Rose Group AG driver et e-handelsapotek og en grossistvirksomhed for medicinske og farmaceutiske produkter under mærkerne Zur Rose og DocMorris i Tyskland, Schweiz og resten af Europa. Selskabet tilbyder produkter inden for forbrugersundhed, skønhed og personlig pleje. Selskabet leverer også ydelser inden for medicinhåndtering. Det driver fysiske apoteksbutikker. Selskabet sælger sine produkter direkte til læger, online postordreapoteker og privatpersoner. Selskabet var tidligere kendt som Zur Rose AG og skiftede navn til Zur Rose Group AG i maj 2015. Zur Rose Group AG blev grundlagt i 1993 og har hovedkontor i Frauenfeld, Schweiz.
| Navn | DocMorris |
| CEO | Walter Hess |
| Hjemsted | Frauenfeld,
th Schweiz |
| Websted | |
| Sektor | Sundhed |
| Branche | Sundhedsudbydere og -tjenester |
| Børsnotering | 06.07.2017 |
| Medarbejdere | 1.454 |
Tickersymboler
| Børs | Symbol |
|---|---|
SIX | ROSE.SW |
Düsseldorf | ZRE.DU |
Frankfurt | ZRE.F |
London | 0RRB.L |
München | ZRE.MU |
Pnk | ZRSEF |
London Stock Exchange | 0RRB.L |
Nse | IITL.NS |
Australian Securities Exchange Ltd | SRX.AX |
Bse | NILA.BO |
Toronto Stock Exchange | EVGN.V |